Primary Care Diabetes
Volume 3, Issue 2 , Pages 97-102 , May 2009

Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice

Received 11 September 2008 ,Revised 27 January 2009 ,Accepted 28 January 2009.

References 

  1. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  2. American Diabetes Association . Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26(Suppl. 1):S28–S32
  3. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2007;30(Suppl. 1):S4–S41
  4. Rutten GEHM, De Grauw WJC, Nijpels G, et al. Standaard diabetes mellitus type 2, tweede herziening. Huisarts en Wetenschap. 2006;49:137–152
  5. American Association of Clinical Endocrinologists . Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. Endocr. Pract. 2002;8(Suppl. 1):40–83
  6. Weyer C, Heinemann L, Heise T. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid acting insulin analog in stable mixture. Diabetes. 1997;20:1612–1614
  7. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin. Ther. 2002;24:530–539
  8. Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes. Metab. 2003;5:446–454
  9. McNally P, Dean J, Morris A, et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044–1048
  10. Boehm BO, Vaz JA, Brondsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur. J Intern. Med. 2004;15:496–502
  11. Davidson J, Liebl A, Christiansen JS, et al. Biphasic insulin aspart is associated with a reduced risk of hypoglycaemia compared with biphasic human insulin. Diabetologia. 2007;50(Suppl. 1):S408
  12. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet. Med. 2002;19:393–399Erratum in: Diabet. Med. 19 (2002) 797
  13. NovoLog® Mix 70/30 Package Insert. http://www.fda.gov/cder/foi/label/2005/021172s021lbl.pdf. Accessed August 5, 2007.
  14. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes. Metab. 2006;8:58–66
  15. Raskin P, Allen E, Hollander P, et al. INITIATE study group Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  16. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care. 2003;26:881–885
  17. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care. 2004;27:17–20
  18. Gough S. Post-marketing surveillance: a UK/European perspective. Curr. Med. Res. Opin. 2005;21:565–570
  19. Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin. Ther. 2007;29:1284–1292
  20. Gough S, Frandsen BK, Toft AD. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study. Diabetes. 2006;55(Suppl. 1):A114 (abstract 477–P)
  21. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086

PII: S1751-9918(09)00004-7

doi: 10.1016/j.pcd.2009.01.003

Primary Care Diabetes
Volume 3, Issue 2 , Pages 97-102 , May 2009

Article Tools

* Image Usage & Resolution